ISI
vs
D
DAX Index
ISI
Over the past 12 months, ISI has significantly outperformed DAX Index, delivering a return of +126% compared to the DAX Index's +13% growth.
Stocks Performance
ISI vs DAX Index
Performance Gap
ISI vs DAX Index
Performance By Year
ISI vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Ionis Pharmaceuticals Inc
Glance View
In the realm of pharmaceutical innovation, Ionis Pharmaceuticals Inc. has carved a niche defined by its pioneering efforts in antisense technology. Founded in 1989, Ionis stands as a trailblazer in the development of RNA-targeted therapies, which deviate from the traditional drug development pathways by focusing on genetic solutions. The company specializes in antisense oligonucleotides—short, synthetic strands of DNA or RNA designed to bind selectively to specific messenger RNA (mRNA). By doing so, they aim to modulate the expression of genes associated with various diseases. This unique approach allows Ionis to address ailments at the genetic level, potentially preventing the production of disease-causing proteins, thus offering alternative therapeutic options for serious diseases. Ionis Pharmaceuticals monetizes its scientific breakthroughs through a diverse revenue stream model. It engages in multiple collaborative partnerships with major pharmaceutical companies, such as Biogen and AstraZeneca, which provide upfront payments, milestone-based fees, and royalties on lucrative antisense drugs that emerge from these alliances. Furthermore, Ionis holds an extensive internal pipeline, advancing proprietary drugs through various stages of research and clinical trials. By strategically balancing in-house projects with external collaborations, Ionis capitalizes on its innovative platform while mitigating financial risks. This dual-strategy not only sustains the company financially but positions it at the forefront of personalized medicine, potentially revolutionizing the landscape of therapeutic development.
